Antimalarial artesunate–mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial
Emmanuel Bottieau,Moustapha Mbow,Isabel Brosius,Clémentine Roucher,Cheikh Tidiane Gueye,Ousmane Thiam Mbodj,Babacar Thiendella Faye,Annelies De Hondt,Bart Smekens,Diana Arango,Christophe Burm,Achilleas Tsoumanis,Linda Paredis,Yven Van Herrewege,Idzi Potters,Joachim Richter,Anna Rosanas-Urgell,Badara Cissé,Souleymane Mboup,Katja Polman
DOI: https://doi.org/10.1038/s41591-023-02719-4
IF: 82.9
2024-01-05
Nature Medicine
Abstract:Schistosomiasis treatment entirely relies on a single drug, praziquantel, prompting research into alternative therapeutics. Here we evaluated the efficacy and safety of the antimalarial combination artesunate–mefloquine for the treatment of schistosomiasis in a proof-of-concept, pragmatic, open-label, randomized controlled trial in primary schools of six villages endemic for schistosomiasis in northern Senegal. Children (6–14 years) were eligible if Schistosoma eggs were detected by microscopy in urine and/or stool. In total, 726 children were randomized 1:1 to praziquantel (standard care: 40 mg kg −1 single dose; n = 364) or to artesunate–mefloquine (antimalarial dosage: artesunate 4 mg kg −1 and mefloquine 8 mg kg −1 daily for three consecutive days; n = 362). Eight children not meeting the inclusion criteria were excluded from efficacy analysis. Median age of the remaining 718 participants was 9 years; 399 (55.6%) were male, and 319 (44.4%) female; 99.3% were infected with Schistosoma haematobium and 15.2% with S. mansoni . Primary outcomes were cure rate, assessed by microscopy, and frequency of drug-related adverse effects of artesunate–mefloquine versus praziquantel at 4 weeks after treatment. Cure rate was 59.6% (208/349) in the artesunate–mefloquine arm versus 62.1% (211/340) in the praziquantel arm. The difference of −2.5% (95% confidence interval (CI) −9.8 to 4.8) met the predefined criteria of noninferiority (margin set at 10%). All drug-related adverse events were mild or moderate, and reported in 28/361 children receiving artesunate–mefloquine (7.8%; 95% CI 5.4 to 11.0) versus 8/363 (2.2%; 95% CI 1.1 to 4.3) receiving praziquantel ( P < 0.001). Artesunate–mefloquine at antimalarial dosage was moderately safe and noninferior to standard-care praziquantel for the treatment of schistosomiasis, predominantly due to S. haematobium . Multicentric trials in different populations and epidemiological settings are needed to confirm these findings. ClinicalTrials.gov identifier: NCT03893097.
biochemistry & molecular biology,cell biology,medicine, research & experimental